JP7734132B2 - 抗血清アルブミン抗体 - Google Patents

抗血清アルブミン抗体

Info

Publication number
JP7734132B2
JP7734132B2 JP2022536639A JP2022536639A JP7734132B2 JP 7734132 B2 JP7734132 B2 JP 7734132B2 JP 2022536639 A JP2022536639 A JP 2022536639A JP 2022536639 A JP2022536639 A JP 2022536639A JP 7734132 B2 JP7734132 B2 JP 7734132B2
Authority
JP
Japan
Prior art keywords
antigen
certain embodiments
binding site
binding
hsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022536639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506834A5 (https=
JP2023506834A (ja
Inventor
パトリック エー． バウアリー
ジェニファー マイケルソン
ポチョン イ
ナヴィーン メータ
ビアンカ プリンツ
ブラッドリー エム． ルンデ
ガー レワ ヒューストン
Original Assignee
カリナン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カリナン セラピューティクス インコーポレイテッド filed Critical カリナン セラピューティクス インコーポレイテッド
Publication of JP2023506834A publication Critical patent/JP2023506834A/ja
Publication of JP2023506834A5 publication Critical patent/JP2023506834A5/ja
Application granted granted Critical
Publication of JP7734132B2 publication Critical patent/JP7734132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022536639A 2019-12-11 2020-12-11 抗血清アルブミン抗体 Active JP7734132B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962946932P 2019-12-11 2019-12-11
US62/946,932 2019-12-11
PCT/US2020/064672 WO2021119531A1 (en) 2019-12-11 2020-12-11 Anti-serum albumin antibodies

Publications (3)

Publication Number Publication Date
JP2023506834A JP2023506834A (ja) 2023-02-20
JP2023506834A5 JP2023506834A5 (https=) 2023-12-18
JP7734132B2 true JP7734132B2 (ja) 2025-09-04

Family

ID=76329090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022536639A Active JP7734132B2 (ja) 2019-12-11 2020-12-11 抗血清アルブミン抗体

Country Status (8)

Country Link
US (1) US20230032087A1 (https=)
EP (1) EP4073114A4 (https=)
JP (1) JP7734132B2 (https=)
CN (1) CN115916816B (https=)
AU (1) AU2020403153A1 (https=)
CA (1) CA3161411A1 (https=)
IL (1) IL293780A (https=)
WO (1) WO2021119531A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293725A (en) 2019-12-11 2022-08-01 Cullinan Oncology Inc Anti-cd19 antibodies and multispecific binding proteins
US20250388663A1 (en) * 2022-08-17 2025-12-25 Institut National de la Santé et de la Recherche Médicale Improved anti-albumin nanobodies and their uses
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
WO2025106915A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
WO2025201474A1 (zh) * 2024-03-28 2025-10-02 诺纳生物（苏州）有限公司 血清白蛋白结合蛋白及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014515602A (ja) 2011-04-01 2014-07-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＶＥＧＦ及びＡｎｇ２と結合する二重特異性結合分子
JP2018517431A (ja) 2015-05-21 2018-07-05 ハープーン セラピューティクス，インク． 三重特異性結合タンパク質と使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101128487B (zh) * 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
HRP20150175T1 (en) * 2005-12-16 2015-03-27 Amgen Research (Munich) Gmbh Means and methods for the treatment of tumorous diseases
DK2211904T3 (en) * 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
AU2016330807B2 (en) * 2015-10-02 2023-08-10 F. Hoffmann-La Roche Ag Anti-human CD19 antibodies with high affinity
KR20180133442A (ko) * 2016-04-13 2018-12-14 비비아 바이오테크 에스.엘. 생체외 bite 활성화된 t 세포
WO2019077062A1 (en) * 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
JP7383704B2 (ja) * 2018-06-07 2023-11-20 カリナン オンコロジー インコーポレイテッド 多重特異性結合タンパク質およびその使用方法
US10815311B2 (en) * 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014515602A (ja) 2011-04-01 2014-07-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＶＥＧＦ及びＡｎｇ２と結合する二重特異性結合分子
JP2018517431A (ja) 2015-05-21 2018-07-05 ハープーン セラピューティクス，インク． 三重特異性結合タンパク質と使用方法

Also Published As

Publication number Publication date
CN115916816B (zh) 2026-02-17
EP4073114A4 (en) 2024-04-17
CN115916816A (zh) 2023-04-04
US20230032087A1 (en) 2023-02-02
CA3161411A1 (en) 2021-06-17
JP2023506834A (ja) 2023-02-20
WO2021119531A1 (en) 2021-06-17
EP4073114A1 (en) 2022-10-19
AU2020403153A1 (en) 2022-06-30
IL293780A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
JP7661446B2 (ja) 多重特異性結合タンパク質およびその使用方法
US12157771B2 (en) Proteins binding NKG2D, CD16 and CLEC12A
US12344672B2 (en) Antibody molecules that bind PD-L1 and CD137
JP7734132B2 (ja) 抗血清アルブミン抗体
EP4347655A1 (en) Anti-ccr8 antibodies and uses thereof
JP7780434B2 (ja) 抗ｃｄ１９抗体および多重特異性結合タンパク質
JP2020536543A (ja) 抗ｃｄ３８抗体および使用方法
HK40091232A (zh) 抗cd19抗体和多特异性结合蛋白
KR20260020379A (ko) 다중특이적 결합 단백질의 사용 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230112

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250731

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250825

R150 Certificate of patent or registration of utility model

Ref document number: 7734132

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150